Cardiawave

Focus: Cardiawave is a France-based biotechnology company developing non-invasive ultrasound therapy for calcific aortic stenosis, a high-prevalence cardiovascular condition. The company operates at pre-revenue stage with a focused pipeline in a large unmet medical need.

Cardiovascular

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Cardiawave

AI assessmentNot Hiring

No open roles listed right now. Follow Cardiawave to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Cardiac Echography

Calcified Aortic Valve

N/A

Clinical Trials (1)

NCT03371524A Prospective RegistrY of Cardiac Echographic Loops

N/A

Help build intelligence for Cardiawave

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity in a high-prevalence disease (calcific aortic stenosis) with limited non-invasive treatment options
Proprietary ultrasound therapy platform represents novel modality differentiation in cardiovascular space
European base provides access to both EU and global cardiovascular markets with growing adoption of minimally invasive therapies

Watch Out For

Extreme early stage with 5 trials across pipeline and no clear phase designation—significant clinical and regulatory uncertainty ahead
Only 2 active job openings signal very limited hiring and small operational footprint with unclear runway or funding status
No public financial data, publications, or recent news available—difficulty assessing company stability, scientific credibility, or near-term milestones

Generated by Claude from Cardiawave's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NIUT

Moderate Aortic Valve Stenosis

N/A

Clinical Trials (1)

NCT06650839POC for the Treatment of Subjects With Moderate AS Using Valvosoft® Non-Invasive Ultrasound Therapy

N/A

VALVOSFT intervention

Aortic Valve Calcification

N/A

Clinical Trials (1)

NCT05235568VALVOSOFT® Pivotal Study

N/A